Giorgio Inghirami
Overview
Explore the profile of Giorgio Inghirami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
217
Citations
9280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morelli E, Ribeiro C, Rodrigues S, Gao C, Socciarelli F, Maisano D, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053701
Purpose: In multiple myeloma (MM), tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step...
2.
Gambi G, Boccalatte F, Rodriguez Hernaez J, Lin Z, Nadorp B, Polyzos A, et al.
Mol Cell
. 2024 Dec;
85(1):42-60.e7.
PMID: 39719705
Cancer progression involves genetic and epigenetic changes that disrupt chromatin 3D organization, affecting enhancer-promoter interactions and promoting growth. Here, we provide an integrative approach, combining chromatin conformation, accessibility, and transcription...
3.
McGrath J, Park J, Troxell C, Chervin J, Li L, Kent J, et al.
Mol Cell
. 2024 Dec;
85(2):430-444.e6.
PMID: 39708804
The efficacy of antibody responses is inherently linked to paratope diversity, as generated through V(D)J recombination and somatic hypermutation. Despite this, it is unclear how genetic diversification mechanisms evolved alongside...
4.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al.
Cancer Cell
. 2024 Dec;
43(1):49-68.e9.
PMID: 39642889
T cell-based immunotherapies have demonstrated effectiveness in treating diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) but predicting response and understanding resistance remains a challenge. To address this,...
5.
Villa M, Sharma G, Malighetti F, Mauri M, Arosio G, Cordani N, et al.
Br J Cancer
. 2024 Oct;
131(11):1781-1795.
PMID: 39478125
Background: Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive T-cell lymphoma, classified into ALK-positive and ALK-negative subtypes, based on the presence of chromosomal translocations involving the ALK gene....
6.
Nguyen D, Hooper W, Liu W, Chu T, Geiger H, Shelton J, et al.
Nature
. 2024 Oct;
635(8037):219-228.
PMID: 39385020
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity. In this study, we investigated the evolution of genomic signatures caused by endogenous and external mutagenic processes...
7.
Abro B, Maurer M, Habermann T, Burack W, Chapman J, Cohen J, et al.
Blood
. 2024 Sep;
144(19):2063-2066.
PMID: 39255410
Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that...
8.
Iqbal J, Inghirami G, Chan W
Blood
. 2024 Aug;
144(18):1873-1886.
PMID: 39213420
Peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group of postthymic T-cell lymphomas with >30 distinct subtypes associated with varied clinicopathological features. Unfortunately, the overall survival of the major PTCL subtypes...
9.
Spriano F, Tarantelli C, Cascione L, Gaudio E, Golino G, Scalise L, et al.
Br J Haematol
. 2024 Jul;
205(5):1873-1882.
PMID: 39080847
Camidanlumab tesirine (ADCT-301) is a CD25-specific antibody-drug conjugate (ADC) employing SG3199, a highly cytotoxic DNA minor groove cross-linking pyrrolobenzodiazepine dimer. The ADC has shown early clinical antitumour activity in various...
10.
Han X, Sui J, Nie K, Zhao Y, Lv X, Xie J, et al.
Leukemia
. 2024 Jul;
38(10):2276-2280.
PMID: 39080353
No abstract available.